Frontline chemoimmunotherapy with nivolumab and dose-adjusted EPOCH in peripheral T-cell lymphoma: a phase 1 trial.

"Conflict-of-interest disclosure: B.H. and P.P. are consultants for Viracta Therapeutics. P.P. receives research funding from Viracta, Innate Pharma, Dren-Bio, ONO, and Teva, and received honoraria or is a consultant for Innate, Daiichi-Sankyo, Kyowa Kirin, Dren-Bio, Lilly-LOXO, and ONO. J.Z. receives grant support from Seattle Genetics, AstraZeneca, CRISPR Therapeutics, and Daiichi Sankyo; receives grant support and is a consultant for Secura Bio and Myeloid Therapeutics; and is a consultant or speaker for Kyowa Kirin. C.S. is the Chief Medical Officer for OncoVerity and RefinedScience. M.K. receives research funding from Novartis; is a consultant for AbbVie, AstraZeneca, Bristol Myers Squibb, Adaptive Biotechnologies, ADC Therapeutics, Beigene, Genentech, Syncopation, and Caribou Biosciences; and is a speaker for Seattle Genetics. The remaining authors declare no competing financial interests."

"Acknowledgment: Bristol Myers Squibb provided financial support for this trial."